Latest event summaries
Event summaries combining transcripts, slides, and related documents. Updated as new events are published.
- DeLLphi-305 showed a significant survival benefit for first-line maintenance IMDELLTRA plus IMFINZI.AMGN
2026 European Society for Medical Oncology (ESMO) Annual Congress - INTerpath-001 cut melanoma recurrence or death risk 42% with intismeran plus pembrolizumab.MRNA
Study update - Zolucatetide posts 72.2% 32-week ORR as a 148-patient Phase 3 targets 2027.PBLS
Investor update - Profit surged YoY as lending and deposits grew; FCNR inflows temporarily diluted NIM.IDFCFIRSTB
Q2 26/27 - PAT rose 53% as deposits and loans grew and asset quality improved.AUBANK
Q2 26/27 - PAT grew 26% as asset quality improved, while NIM fell to 4.31%.KOTAKBANK
Q2 26/27 - Maize-led profit surge underpins fermentation and wet-milling expansion.GAEL
Q2 26/27 - Povetacicept cut IgAN proteinuria 52.0%; AMPLITUDE interim data target early 2027.VRTX
American Society of Nephrology (ASN) Kidney Week 2026 - REMODEL success supports a $4bn+ RMS opportunity for remibrutinib.NOVN
Investor update - Clinical evidence aims to fuel recurring use and 2027 adjusted EBITDA positivity.ZOM
Investor update - Tax credits lifted Q3 earnings as NIM eased and uninsured deposits rose.MCBS
Q3 2026 - Q3 earnings rebounded QoQ as margin widened, while 9M profit trailed 2025.OVLY
Q3 2026 - VMT-α-NET showed 50% ORR in Cohort 3 and 71.9% PFS at 18 months.CATX
Study update - Loan interest reversals pressured Q3 earnings and NIM as deposits grew and the loan pipeline strengthened.PFBC
Q3 2026 - All ballot items passed, including a potential 1-for-5 to 1-for-15 share consolidation.WEED
AGM 2026 - NIM rose to 3.30% as credit costs climbed and loan-growth guidance fell.FHB
Q3 2026